Rallybio (RLYB) Stock Overview

A clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. More details

RLYB fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	3/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 97.7% below our estimate of its fair value

Earnings are forecast to grow 67.56% per year

Became profitable this year

Trading at good value compared to peers and industry

Risk Analysis

High level of non-cash earnings

Makes less than USD$1m in revenue ($646K)

Does not have a meaningful market cap ($90M)

RLYB Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,300 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

440,300 investors already sharing narratives

View all narratives

Rallybio Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Rallybio
Historical stock prices
Current Share Price	US$16.88
52 Week High	US$17.57
52 Week Low	US$3.67
Beta	-0.85
1 Month Change	-0.68%
3 Month Change	6.13%
1 Year Change	251.09%
3 Year Change	-57.21%
5 Year Change	-83.51%
Change since IPO	-85.04%

Recent updates

Analysis Article • Jul 10

We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Analysis Article • Aug 28

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analysis Article • Jan 04

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Sep 19

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analysis Article • May 15

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Analysis Article • Jan 30

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Oct 31

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analysis Article • Jul 07

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analysis Article • Mar 16

Rallybio (NASDAQ:RLYB) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Shareholder Returns

	RLYB	US Biotechs	US Market
7D	-0.3%	-5.3%	-1.0%
1Y	251.1%	37.0%	14.1%

Return vs Industry: RLYB exceeded the US Biotechs industry which returned 37% over the past year.

Return vs Market: RLYB exceeded the US Market which returned 14.1% over the past year.

Price Volatility

Is RLYB's price volatile compared to industry and market?
RLYB volatility
RLYB Average Weekly Movement	2.6%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

Stable Share Price: RLYB has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: RLYB's weekly volatility has decreased from 13% to 3% over the past year.

About the Company

Founded	Employees	CEO	Website
2018	7	Steve Uden	www.rallybio.com

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia.

Rallybio Corporation Fundamentals Summary

How do Rallybio's earnings and revenue compare to its market cap?
RLYB fundamental statistics
Market cap	US$89.61m
Earnings (TTM)	US$45.55m
Revenue (TTM)	US$646.00k

2.0x

P/E Ratio

138.7x

P/S Ratio

Is RLYB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RLYB income statement (TTM)
Revenue	US$646.00k
Cost of Revenue	US$9.83m
Gross Profit	-US$9.18m
Other Expenses	-US$54.73m
Earnings	US$45.55m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	8.58
Gross Margin	-1,421.21%
Net Profit Margin	7,051.24%
Debt/Equity Ratio	0%

How did RLYB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/13 02:23
End of Day Share Price	2026/09/11 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rallybio Corporation is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jonathan Wolleben	Citizens JMP Securities, LLC
Eun Kyung Yang	Jefferies LLC
Ritu Baral	TD Cowen

Rallybio (RLYB) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Rallybio Corporation Competitors

ImmuCell

Vaxart

CapForce

Compugen

Price History & Performance

Recent News & Updates

Avenzo Therapeutics, Inc. entered into a definitive agreement to acquire Rallybio Corporation (NasdaqCM:RLYB) in a reverse merger transaction.

Candid Therapeutics, Inc. cancelled the acquisition of Rallybio Corporation (NasdaqCM:RLYB) in a reverse merger transaction.

Candid Therapeutics, Inc. agreed to acquire Rallybio Corporation (NasdaqCM:RLYB) in a reverse merger transaction.

Rallybio Corporation Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Rallybio Announces Reverse Stock Split of Common Stock to Satisfy the Minimum Price Requirement for Continued Listing on the Nasdaq Capital Market

Rallybio Corporation Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Recent updates

Avenzo Therapeutics, Inc. entered into a definitive agreement to acquire Rallybio Corporation (NasdaqCM:RLYB) in a reverse merger transaction.

Candid Therapeutics, Inc. cancelled the acquisition of Rallybio Corporation (NasdaqCM:RLYB) in a reverse merger transaction.

Candid Therapeutics, Inc. agreed to acquire Rallybio Corporation (NasdaqCM:RLYB) in a reverse merger transaction.

Rallybio Corporation Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Rallybio Announces Reverse Stock Split of Common Stock to Satisfy the Minimum Price Requirement for Continued Listing on the Nasdaq Capital Market

Rallybio Corporation Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Nasdaq Transfers Rallybio Corporation Listing to Nasdaq Capital Market, Eligible for an Additional 180 Calendar Day Period to Regain Compliance with the Minimum Closing Bid Price Requirement

New major risk - Financial position

We're Keeping An Eye On Rallybio's (NASDAQ:RLYB) Cash Burn Rate

Rallybio Corporation Initiates Dosing in Rlyb116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Price target increased by 24% to US$10.50

Rallybio Corporation to Discontinue Development of RLYB212 for Prevention of FNAIT

Rallybio Corporation, Annual General Meeting, May 13, 2025

New minor risk - Share price stability

No longer forecast to breakeven

Rallybio Corporation Receives Non-Compliance Letter from Nasdaq Regarding Bid Price Requirement

Rallybio Corporation Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

Forecast to breakeven in 2027

Rallybio Corporation Announces Promising RLYB212 and RLYB332 Preclinical Data at 66th American Society of Hematology Annual Meeting

Rallybio Corporation Announces to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

Rallybio Corporation Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

Consensus revenue estimates increase by 33%

Rallybio Corporation Announces Initiation of Phase 2 Clinical Trial of RLYB212

Consensus EPS estimates upgraded to US$1.34 loss

New minor risk - Profitability

Rallybio Announces Publication of RLYB212 Phase 1 Proof-Of-Concept Study Results in Thrombosis and Haemostasis

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully

Price target decreased by 19% to US$10.50

Rallybio Corporation(NasdaqGS:RLYB) dropped from Russell 3000 Index

Rallybio Corporation Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Rlybocytopenia

Ralebio Corporation Announces the Presentation of Results from FNAIT Systematic Literature Review and Meta- Analysis At the Academy of Managed Care Pharmacy 2024 Annual Meeting

Rallybio Corporation, Annual General Meeting, May 15, 2024

Rallybio Corporation announced that it has received $6.599999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Price target decreased by 32% to US$9.38

Rallybio Corporation Announces the Prioritization of Its Portfolio and a 45% Workforce Reduction to Focus Resources on Its Phase 2-Ready Clinical Stage Programs

Is Rallybio (NASDAQ:RLYB) In A Good Position To Deliver On Growth Plans?

Rallybio Corporation Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116

Rallybio Corporation Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212

New major risk - Share price stability

New minor risk - Market cap size

Rallybio Corporation Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting

Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?

Rallybio Corporation Presents Phase 1 Single Ascending Dose Data for RLYB116, Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Price target decreased by 7.3% to US$16.83

Rallybio Corporation Announces Executive Changes

Rallybio Corporation Reports Data from the Phase 1b Proof-Of-Concept Study of RLYB212

Price target decreased by 9.9% to US$18.17

Rallybio to Present Data from the RLYB212 Phase 1b Proof-Of-Concept Study

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Price target decreased by 7.2% to US$22.50

Rallybio Corporation Announces Chief Financial Officer Changes

We Think Rallybio (NASDAQ:RLYB) Can Afford To Drive Business Growth

Rallybio Announces Publication of Data Highlighting the Ability of HPA-1A-Specific Antibodies to Prevent Alloimmunization in an Authentic Mouse Model of FNAIT

Price target decreased to US$28.00

High number of new directors

Rallybio Announces Positive Phase 1 Single Ascending Dose Results for RLYB116, an Innovative Subcutaneously Injected Inhibitor of Complement Component 5

Here's Why We're Not Too Worried About Rallybio's (NASDAQ:RLYB) Cash Burn Situation

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

Price target increased to US$30.67

Rallybio Corporation Expects to Discuss the Preliminary Platelet Elimination Data by the End of the Third Quarter of 2022